Comparison of Microbiome Composition and Biomarkers in Pharmaco Resistant and Pharmaco-Sensitive Epilepsy

Exclusion Criteria

• •Study participant has monogenic epilepsy.
• •Study participant has a neurodegenerative disease, mitochondrial disease, metabolic disease, active central nervous system disease, active autoimmune disease, or active inflammatory bowel disease.
• •Study participant is on, or has been on within 30 days prior to the Screening Visit, a ketogenic diet, low glycemic index diet, or modified Atkins diet therapy.
• •Study participant has had surgery within 3 months of the Screening Visit.
• •Study participant is a resident in a group or hospital setting.
• •Study participant requires the use of a g-tube or formula feeding.
• •Study participant has had antibiotic therapy within 60 days prior to the Screening Visit.
• •Study participant has participated in the study of an investigational product within 3 months prior to the Screening Visit (or within 5 half lives of the investigational product, whichever is longer) or is currently participating in a study of an investigational product.